EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prospective evaluation of donor-derived cell-free DNA for noninvasive detection of acute rejection in an Asian heart transplant population

Shanshan Zheng, Sheng Liu, Zhiyuan Zhu, Jie Huang, Zhongkai Liao, Zhe Zheng, Xiaonan Fang, Lin Zhang, Hang Xu, Jiexu Ma, Yige Huyan, Xinhe Xu und 1 weitere

Transplant International · 2026

DOI: 10.3389/ti.2026.16415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant International, 2026. Verfasst von Shanshan Zheng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Heart Transplantation, Cell-Free Nucleic Acids, Graft Rejection. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endomyocardial biopsy (EMB) is the gold standard for diagnosing post-heart transplant acute rejection (AR) but is invasive. Donor-derived cell-free DNA (dd-cfDNA) is a promising noninvasive biomarker, yet thresholds for Asian recipients remain undefined. This prospective study enrolled 80 patients, with 299 dd-cfDNA specimens analyzed via a novel Chinese-developed next-generation sequencing assay targeting 48 Indel sites. A reference cohort (n = 42) established post-transplant dd-cfDNA kinetics, while a biopsy cohort (n = 41, 18 acute cellular rejection [ACR], 9 antibody-mediated rejection [AMR], 14 no rejection [NR]) paired with EMB evaluated diagnostic performance. dd-cfDNA peaked at week 1, with a stable trend emerging from week 4 and stable levels reached by week 8. AR patients had significantly higher dd-cfDNA levels than NR patients (0.87% vs. 0.23%, P < 0.001). The optimal composite AR threshold was 0.33% (AUC = 0.874, sensitivity 81.0%, specificity 85.7%). dd-cfDNA decreased post-therapy (P = 0.011) and showed an inverse association with left ventricular ejection fraction (LVEF) (P = 0.004). This study provides initial evidence for an assay- and cohort-specific dd-cfDNA threshold (0.33%) for AR detection in Chinese recipients. Given the modest NPV (75.0%), this threshold is better suited for a “rule-in” strategy, and low values should not be used in isolation to defer biopsy. External validation in multicenter cohorts is required before routine clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart TransplantationCell-Free Nucleic AcidsGraft RejectionHumansFemaleProspective StudiesMaleMiddle AgedAdultAsian PeopleBiomarkersBiopsyTissue DonorsAcute DiseaseSensitivity and Specificity

Stichwörter der Autor:innen

acute rejectionbiomarkersdonor-derived cell-free DNAheart transplantationnoninvasive monitoring

Substanzen

Cell-Free Nucleic AcidsBiomarkers

Autor:innen und Institutionen

  • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Zitieren

APA

Zheng, S., Liu, S., Zhu, Z., Huang, J., Liao, Z., Zheng, Z., Fang, X., Zhang, L., Xu, H., Ma, J., Huyan, Y., Xu, X., & Zou, Z. (2026). Prospective evaluation of donor-derived cell-free DNA for noninvasive detection of acute rejection in an Asian heart transplant population. Transplant International. https://doi.org/10.3389/ti.2026.16415

Vancouver

Zheng S, Liu S, Zhu Z, Huang J, Liao Z, Zheng Z, et al. Prospective evaluation of donor-derived cell-free DNA for noninvasive detection of acute rejection in an Asian heart transplant population. Transplant International. 2026. doi:10.3389/ti.2026.16415

BibTeX
@article{Zheng2026,
  author = {Zheng, Shanshan and Liu, Sheng and Zhu, Zhiyuan and Huang, Jie and Liao, Zhongkai and Zheng, Zhe and Fang, Xiaonan and Zhang, Lin and Xu, Hang and Ma, Jiexu and Huyan, Yige and Xu, Xinhe and Zou, Zhengbang},
  title = {Prospective evaluation of donor-derived cell-free DNA for noninvasive detection of acute rejection in an Asian heart transplant population},
  journal = {Transplant International},
  year = {2026},
  doi = {10.3389/ti.2026.16415}
}
Kostenlos starten →